|1.||Solca, Flavio: 3 articles (06/2014 - 05/2007)|
|2.||de Bono, Johann S: 2 articles (02/2014 - 09/2010)|
|3.||Wheatley, Duncan: 2 articles (02/2014 - 06/2012)|
|4.||Temple, Graham: 2 articles (02/2014 - 09/2010)|
|5.||Hickish, Tamas: 2 articles (02/2014 - 06/2012)|
|6.||Zips, Daniel: 2 articles (01/2014 - 05/2007)|
|7.||Baumann, Michael: 2 articles (01/2014 - 05/2007)|
|8.||Krause, Mechthild: 2 articles (01/2014 - 05/2007)|
|9.||Eicheler, Wolfgang: 2 articles (01/2014 - 05/2007)|
|10.||Wong, Kwok-Kin: 2 articles (11/2012 - 01/2009)|
|1.||Lung Neoplasms (Lung Cancer)
08/07/2008 - "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models."
08/07/2008 - "These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes."
06/01/2015 - "In the present study, we assessed whether the combination of suberoylanilide hydroxamic acid (SAHA, vorinostat), a potent HDAC inhibitor, and BIBW2992 or WZ4002 could overcome EGFR TKI resistance associated with T790M mutation in lung cancer cells. "
03/15/2012 - "The effects of E7050 on HGF-induced resistance to reversible (gefitinib), irreversible (BIBW2992), and mutant-selective (WZ4002) EGFR-TKIs were determined using the EGFR mutant human lung cancer cell lines PC-9 and HCC827 with an exon 19 deletion and H1975 with an T790M secondary mutation. "
07/01/2014 - "Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation."
03/01/2011 - "Preclinical and clinical data pertaining to BIBW 2992 in advanced solid tumors, and particularly in NSCLC, are also thoroughly reviewed. "
06/01/2015 - "Finally, the combined treatment with SAHA and either BIBW2992 or WZ4002 showed an enhanced anti-tumor effect on xenografts of H1975 cells in vivo. "
12/01/2008 - "In phase I/II trials, BIBW-2992 was effective in patients with solid tumors, including those with NSCLC tumors activating mutations in the EGFR tyrosine kinase domain. "
06/01/2013 - "Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors."
09/01/2010 - "Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors."
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/01/2011 - "Afatinib (BIBW 2992) development in non-small-cell lung cancer."
03/01/2011 - "BIBW 2992 in non-small cell lung cancer."
12/01/2010 - "EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992."
06/01/2014 - "Afatinib (also known as BIBW 2992) has recently been approved in several countries for the treatment of a distinct type of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. "
01/13/2009 - "Based on these findings, clinical testing of the BIBW2992/rapamycin combination in non-small cell lung cancer patients with tumors expressing HER2 mutations is warranted."
|4.||Prostatic Neoplasms (Prostate Cancer)
12/01/2008 - "At the time of publication, BIBW-2992 was undergoing phase II trials for NSCLC, breast and prostate cancers, head and neck carcinoma, as well as glioma. "
02/01/2014 - "The aim of this article was to evaluate afatinib (BIBW 2992), an ErbB family blocker, and nintedanib (BIBF 1120), a triple angiokinase inhibitor, in castration-resistant prostate cancer patients. "
|5.||Osteosarcoma (Osteogenic Sarcoma)
|1.||erlotinib (CP 358,774)
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|6.||Epidermal Growth Factor Receptor (EGF Receptor)
|10.||vorinostat (suberoylanilide hydroxamic acid)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)